Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease (GVHD) in the Netherlands

Richardson MD (2005) Changing patterns and trends in systemic fungal infections. J Antimicrob Chemother 56(Suppl 1):i5–i11

Hagen EA, Stern H, Porter D, Duffy K, Foley K, Luger S, Schuster SJ, Stadtmauer EA, Schuster MG (2003) High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 36:9–15

Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II (2005) Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 5:775–785

Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916–1924

Jansen JP, Meis JF, Blijlevens NM, van’t Wout JW (2005) Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands. Curr Med Res Opin 21:1535–1546

Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845–851

Slavin MA, Osborne B, Adams R, Levenstein MJ, Schoch HG, Feldman AR, Meyers JD, Bowden RA (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation–a prospective, randomized, double-blind study. J Infect Dis 171:1545–1552

Dixon DM, McNeil MM, Cohen ML, Gellin BG, La Montagne JR (1996) Fungal infections: a growing threat. Public Health Rep 111:226–235

Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP (1999) Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis 29:239–244

Groll AH, Walsh TJ (2001) Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect 7(Suppl 2):8–24

Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais dA, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356:335–347

Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359

Stam WB, O’Sullivan AK, Rijnders B, Lugtenburg E, Span LF, Janssen JJ, Jansen JP (2008) Economic evaluation of posaconazole versus standard azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol 81(6):467–474

Wingard JR, Piantadosi S, Vogelsang GB, Farmer ER, Jabs DA, Levin LS, Beschorner WE, Cahill RA, Miller DF, Harrison D (1989) Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. Blood 74:1428–1435

Centraal Bureau voor de Statistiek. CBS STATLINE Overlevingstafels 2005. http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA=37360ned&D1=3&D2=a&D3=a&D4=55&HDR=G1,T&STB=G3,G2&VW=T

Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC, Antin JH (1997) Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. Ann Intern Med 127:1080–1088

Nietert PJ, Silverstein MD, Abboud MR (2002) Sickle cell anaemia: epidemiology and cost of illness. Pharmacoeconomics 20:357–366

Z-index B.V. (2007) Z-Index taxe: selection of the G standard drug databank. Z-index B.V., The Haag

College voor Zorgverzekeringen (2006) Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie. College voor Zorgverzekeringen, Diemen

Briggs A, Sculpher M, Buxton M (1994) Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ 3:95–104

Jantunen E, Ruutu P, Niskanen L, Volin L, Parkkali T, Koukila-Kahkola P, Ruutu T (1997) Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 19:801–808

Marr KA, Carter RA, Crippa F, Wald A, Corey L (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34:909–917

De Pauw BE, Donnelly JP (2007) Prophylaxis and aspergillosis–has the principle been proven? N Engl J Med 356:409–411

Carlens S, Ringden O, Remberger M, Lonnqvist B, Hagglund H, Klaesson S, Mattsson J, Svahn BM, Winiarski J, Ljungman P, Aschan J (1998) Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 22:755–761

Remberger M, Kumlien G, Aschan J, Barkholt L, Hentschke P, Ljungman P, Mattsson J, Svennilson J, Ringden O (2002) Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 8:674–682

Jonsson B (2004) Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds. Pharmacoeconomics 22(Suppl 4):5–10

Council for Public Health and Healthcare (2006) Sensible and sustainable care. Council for Public Health and Healthcare, The Hague

Stolk EA, Poley MJ (2005) Criteria for determining a basic health services package. Recent developments in The Netherlands. Eur J Health Econ 6:2–7

Groot MT, van Agthoven M, Lowenberg B, Willemze R (2004) Uyl-de Groot CA [The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation]. Ned Tijdschr Geneeskd 148:480–484